triethyl-amine; triethylammonium cyanide | 28871-28-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: triethyl-amine; triethylammonium cyanide
• 英文别名: Triaethyl-amin; Triaethylammoniumcyanid；triethylammonium cyanide；Triathylammoniumcyanid；triethylazanium;cyanide
• CAS: 28871-28-5
• 化学式: CN*C₆H₁₅N*H
• 分子量: 128.217
• InChiKey: DSNKGSSXSYPWNC-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  1.56
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  cis-4'-hydroxyspiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-3-one 、 triethyl-amine; triethylammonium cyanide 、 甲基磺酰氯 在 三乙胺 作用下， 以 N-甲基乙酰胺 为溶剂， 生成 trans-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carbonitrile
  参考文献：
  名称：

  Spiro compounds

  摘要：

  通用式（I）的化合物：其中Ar1代表可选择取代的芳基或杂环芳基；n代表0或1；T、U、V和W分别独立地代表氮原子或可选择取代的甲基基团，其中至少有两个代表所述的甲基基团；X代表甲基或羟基取代的甲基；Y代表可选择取代的亚胺基或氧原子。这些新颖的螺环化合物可用作神经肽Y受体拮抗剂，以及治疗各种心血管疾病、中枢神经系统疾病、代谢性疾病等的药物。

  公开号：

  US06803372B2

文献信息

• Novel spiro compounds
  申请人：——

  公开号：US20020188124A1

  公开（公告）日：2002-12-12

  Compounds of the general formula (I): 1 wherein Ar 1 represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.

  通式(I)的化合物： 1 其中Ar 1 代表可选地取代的芳基或杂芳基； n代表0或1； T、U、V和W各自独立地代表氮原子或可选地取代的次甲基基团，其中至少有两个代表所述次甲基基团； X代表次甲基或羟基取代的次甲基； Y代表可选地取代的亚氨基或氧原子被描述和声称。这些新型的螺环化合物作为神经肽Y受体拮抗剂以及用于治疗各种心血管疾病、中枢神经系统疾病、代谢性疾病等的药物是有用的。
• 2-aminopyridines containing fused ring substituents
  申请人：——

  公开号：US20010049379A1

  公开（公告）日：2001-12-06

  The present invention relates to 2-aminopyridine derivatives of the formula 1 wherein G, R 1 and R 2 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

  本发明涉及公式1中定义的G、R1和R2的2-氨基吡啶衍生物，其表现为一氧化氮合酶（NOS）抑制剂的活性，以及含有它们的药物组合物，并且它们在治疗和预防中枢神经系统和其他疾病中的应用。
• METHOD FOR PRODUCING 3-AMINOMETHYLTETRAHYDROFURAN DERIVATIVE
  申请人：Mitsui Chemicals, Inc.

  公开号：EP1780205A1

  公开（公告）日：2007-05-02

  An object of the present invention is to provide a process for producing a 3-cyanotetrahydrofuran derivative in a high yield from inexpensive industrial materials. According to the present invention, a 3-aminomethyltetrahydrofuran derivative is produced by preparing a 3-cyanotetrahydrofuran derivative in a high yield from an inexpensive and industrially easily available malic acid derivative, and reducing the cyano group of the 3-cyanotetrahydrofuran derivative.

  本发明的一个目的是提供一种从廉价的工业原料中高产率生产3-氰基四氢呋喃衍生物的方法。根据本发明，通过从廉价且工业上易获得的苹果酸衍生物制备高产率的3-氰基四氢呋喃衍生物，然后还原3-氰基四氢呋喃衍生物的氰基，从而制备3-氨甲基四氢呋喃衍生物。
• Branched alkoxy-subsituted 2-aminopyridines
  申请人：——

  公开号：US20020022642A1

  公开（公告）日：2002-02-21

  The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula 1 wherein R 1 , R 2 , R 3 and R 4 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

  本发明涉及式1中R1、R2、R3和R4如规范中定义的6-苯基吡啶-2-胺衍生物，其具有作为一氧化氮合酶（NOS）抑制剂的活性，以及含有它们的药物组合物，并用于治疗和预防中枢神经系统和其他疾病。
• PHARMACEUTICAL USES FOR NOS INHIBITORS
  申请人：——

  公开号：US20020151572A1

  公开（公告）日：2002-10-17

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (N-NOS) inhibitors: (a) alone or in combination with another active agent for the treatment of psoriasis; (b) in combination with an antiinflammatory agent for the treatment of inflammatory disorders; (c) in combination with a narcotic analgesic (e.g., opiates such as morphine or demerol) for the treatment of pain; (d) alone or in combination with other active agents for the enhancement of cognition; and (e) alone or in combination with other active agents for the treatment of sleep disorders such as apnea, narcolepsy and insomnia.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药用途。具体而言，涉及使用NOS抑制剂，特别是选择性神经元NOS（N-NOS）抑制剂：（a）单独或与另一活性剂结合用于治疗牛皮癣；（b）与抗炎药物结合用于治疗炎症性疾病；（c）与麻醉镇痛剂（例如吗啡或度冷丁等阿片类药物）结合用于治疗疼痛；（d）单独或与其他活性剂结合用于增强认知功能；以及（e）单独或与其他活性剂结合用于治疗呼吸暂停、白天疲劳和失眠等睡眠障碍。